StreetInsider.com News Articles

Form 8-K BOSTON SCIENTIFIC CORP For: Oct 01

Wed, 07 Oct 2026 06:12:00 -0400

si-local-file:///var/storage/secattach/20261007/27157575.html

Boston Scientific names new COO, restructures into three segments

Wed, 07 Oct 2026 06:00:24 -0400

Boston Scientific Corporation (NYSE: BSX) announced the appointment of Joseph M. Fitzgerald as executive vice president and chief operating officer, effective Jan. 1, 2027. In the role, Fitzgerald will oversee the company's global operations, business units and regions.

Fitzgerald currently serves as executive vice president and group president, Cardiovascular, at Boston Scientific. He will report to Chairman and CEO Mike Mahoney.

Concurrent with the appointment, Boston Scientific will reorganize into three reportable segments, also effective Jan. 1, 2027: Interventional Therapies, Rhythm Solutions and MedSurg.

Interventional Therapies will include the Interventional Cardiology, Vascular Therapies and Interventional Oncology & Embolization businesses, and will be led

Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer

Wed, 07 Oct 2026 06:00:00 -0400

New operating structure designed to increase efficiency and support continued growth

MARLBOROUGH, Mass., Oct. 7, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Joseph M. Fitzgerald to executive vice president and chief operating officer (COO), effective Jan. 1, 2027. In this role, Fitzgerald will oversee the company's global operations, business units and regions.

Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer

Wed, 07 Oct 2026 06:00:00 -0400

New operating structure designed to increase efficiency and support continued growth

Barclays Starts Boston Scientific (BSX) at Equalweight

Tue, 06 Oct 2026 16:25:15 -0400

Barclays analyst ` initiates coverage on Boston Scientific (NYSE: BSX) with a Equalweight rating and a price target of $48.00.

For an analyst ratings summary and ratings history on Boston Scientific click here. For more ratings news on Boston Scientific click here.

Shares of Boston Scientific closed at $42.40 yesterday.

Boston Scientific (BSX) PT Lowered to $54 at Bernstein SocGen Group

Mon, 05 Oct 2026 08:22:17 -0400

Bernstein SocGen Group analyst Lee Hamnright lowered the price target on Boston Scientific (NYSE: BSX) to $54.00 (from $60.00) while maintaining an Outperform rating.

The analyst commented: "Abbott's Amulet 360 can take share from BSX Watchman. The KOL believes ABT’s next-generation device appears to have addressed legacy safety concerns and could take meaningful share from WATCHMAN over time, doubling from 10% share to 20% in the near term and potentially approaching a 50/50 split with BSX. ABT may also benefit from the ability to bundle EP and LAAC portfolios, particularly as concomitant procedures become an increasingly important part of the market.

Boston Scientific (BSX) PT Lowered to $54 at Bernstein SocGen Group

Mon, 05 Oct 2026 08:22:17 -0400

Bernstein SocGen Group analyst Lee Hamnright lowered the price target on Boston Scientific (NYSE: BSX) to $54.00 (from $60.00) while maintaining an Outperform rating.

Citi Adjusts Catalyst Watch List

Mon, 05 Oct 2026 06:57:43 -0400

Citi Adjusts Catalyst Watch List.

Sight Sciences (NASDAQ: SGHT) adds to 90-Day upside catalyst watch list.
Zimmer Biomet Holdings (NYSE: ZBH) adds to 90-Day upside catalyst watch list.
Edwards Lifesciences (NYSE: EW) adds to 90-Day upside catalyst watch list.
Boston Scientific (NYSE: BSX) adds to 90-Day upside catalyst watch list.

Citi Adjusts Catalyst Watch List

Mon, 05 Oct 2026 06:57:43 -0400

Citi Adjusts Catalyst Watch List.

Sight Sciences (NASDAQ: SGHT) adds to 90-Day upside catalyst watch list.
Zimmer Biomet Holdings (NYSE: ZBH) adds to 90-Day upside catalyst watch list.
Edwards Lifesciences (NYSE: EW) adds to 90-Day upside catalyst watch list.
Boston Scientific (NYSE: BSX) adds to 90-Day upside catalyst watch list.

Citi Adjusts Catalyst Watch List

Mon, 05 Oct 2026 06:57:43 -0400

Citi Adjusts Catalyst Watch List.

Sight Sciences (NASDAQ: SGHT) adds to 90-Day upside catalyst watch list.
Zimmer Biomet Holdings (NYSE: ZBH) adds to 90-Day upside catalyst watch list.
Edwards Lifesciences (NYSE: EW) adds to 90-Day upside catalyst watch list.
Boston Scientific (NYSE: BSX) adds to 90-Day upside catalyst watch list.

Citi Adjusts Catalyst Watch List

Mon, 05 Oct 2026 06:57:43 -0400

Citi Adjusts Catalyst Watch List.

Sight Sciences (NASDAQ: SGHT) adds to 90-Day upside catalyst watch list.
Zimmer Biomet Holdings (NYSE: ZBH) adds to 90-Day upside catalyst watch list.
Edwards Lifesciences (NYSE: EW) adds to 90-Day upside catalyst watch list.
Boston Scientific (NYSE: BSX) adds to 90-Day upside catalyst watch list.

Elutia receives $8M escrow payment from Boston Scientific

Thu, 01 Oct 2026 16:49:55 -0400

Elutia Inc. (Nasdaq: ELUT) announced it has received an $8 million escrow payment from Boston Scientific Corporation (NYSE: BSX), completing a holdback period tied to the October 2025 sale of its BioEnvelope business for $88 million.

The payment was released with no indemnity claims following the one-year holdback period. Elutia said the company is now funded through the first full year of its planned NXT-41x commercial launch and into 2029, without the need for an equity offering.

The escrow release is the third of three funding milestones the company outlined in its second quarter earnings release. The other two were the closing

Elutia receives $8M escrow payment from Boston Scientific

Thu, 01 Oct 2026 16:49:55 -0400

The escrow release is the third of three funding milestones the company outlined in its second quarter earnings release. The other two were the closing

Boston Scientific wins $135.7M military cardiovascular supply contract

Mon, 28 Sep 2026 17:19:23 -0400

Boston Scientific Corp. has been awarded a contract worth up to $135,683,214 by the U.S. Department of Defense for cardiovascular procedural packages and ancillary items, according to a government announcement.

The firm-fixed-price, indefinite-delivery/indefinite-quantity contract with economic price adjustment runs for five years, with an ordering period end date of Sept. 29, 2031. There are no option periods.

The contract was awarded as a sole-source acquisition under 10 U.S. Code 3204 (a)(1), as cited in Federal Acquisition Regulation 6.302-1. The using military services are the Army, Navy, and Air Force.

Funding will come from fiscal years 2026 through 2031 defense working capital funds. The

Boston Scientific (BSX) PT Lowered to $48 at Wells Fargo

Thu, 24 Sep 2026 06:03:47 -0400

Wells Fargo analyst Larry Biegelsen lowered the price target on Boston Scientific (NYSE: BSX) to $48.00 (from $50.00) while maintaining a Equal Weight rating.

The analyst comments "We lowe"r our Q3 est's by our estimated net impact to BSX from the eight days of downtime of ~$300M in sales & ~$0.13 EPS. We assume no procedure recapture/ inventory build in Q4 and no change to our growth est's in 2027+, which could be conservative. Recall that as of Sept 9, BSX operations have been fully restored post-cyberattack after eight days of impact. The company is still working through what the recapture

Boston Scientific (BSX) PT Lowered to $48 at Wells Fargo

Thu, 24 Sep 2026 06:03:47 -0400

Wells Fargo analyst Larry Biegelsen lowered the price target on Boston Scientific (NYSE: BSX) to $48.00 (from $50.00) while maintaining a Equal Weight rating.

Boston Scientific executive to retire in early 2027

Wed, 23 Sep 2026 06:07:44 -0400

Arthur C. Butcher, Executive Vice President and Group President of MedSurg and Asia Pacific at Boston Scientific (NYSE: BSX), has informed the company of his plan to retire effective January 1, 2027.

Following his retirement, Butcher is expected to remain with the company as a senior advisor through February 26, 2027. In that role, he will receive a prorated base salary at his current annual rate of $780,000.

Butcher communicated his retirement decision to the company on September 21, 2026.

Boston Scientific executive to retire in early 2027

Wed, 23 Sep 2026 06:07:44 -0400

Arthur C. Butcher, Executive Vice President and Group President of MedSurg and Asia Pacific at Boston Scientific (NYSE: BSX), has informed the company of his plan to retire effective January 1, 2027.

Butcher communicated his retirement decision to the company on September 21, 2026.

Form 8-K BOSTON SCIENTIFIC CORP For: Sep 21

Wed, 23 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260923/27092947.html

Boston Scientific (BSX) call put ratio 1.8 calls to 1 put with a focus on 25K contracts of December 75 calls

Thu, 17 Sep 2026 15:07:14 -0400

Boston Scientific (NYSE: BSX) 30-day option implied volatility is at 38; compared to its 52-week range of 21 to 55. Call put ratio 1.8 calls to 1 put with a focus on 25K contracts of December 75 calls trading at 10c.

TD Cowen Boston Scientific (BSX): 'We Maintain Our Constructive 2027-Based View'

Thu, 17 Sep 2026 09:39:49 -0400

TD Cowen analyst Joshua Jennings reiterated a Buy rating and $56.00 price target on Boston Scientific (NYSE: BSX).

The analyst commented: "Reducing Estimates for Cyberattack; We Maintain Our Constructive '27-Based View; We have lowered our estimates to account for the H2'26 impact of the Aug 25 cyberattack. BSX has not yet quantified the impact beyond saying that it is now unlikely to meet its guidance for Q3 and full-year 2026, so our revisions rely on our own assumptions. Though estimate cuts are rarely positive, the driver here is a one-time event. Our constructive view that is based on 2027 remains unchanged."

For

Citi downgrades Boston Scientific on uncertain recovery path

Thu, 17 Sep 2026 07:46:00 -0400

Investing.com -- Citi has downgraded Boston Scientific to Neutral from Buy, citing an uncertain recovery path after a string of setbacks this year.

Analyst Joanne Wuensch cut her price target for the stock to $50 from $57, saying the medical device maker's fortunes have "shifted in a big way" in 2026.

She pointed to a more mature and competitive U.S. market for pulsed field ablation, a stagnating left atrial appendage closure market, hiccups in urology, and a cybersecurity attack.

Wuensch said Citi has lowered its estimates eight times this year, most recently on Sept. 9, and while she would like to

Citi cuts Boston Scientific rating to neutral, lowers price target

Thu, 17 Sep 2026 05:03:55 -0400

(Updated - September 17, 2026 5:03 AM EDT)

Citi analyst Joanna Wuensch downgraded Boston Scientific (NYSE: BSX) from Buy to Neutral, reducing the price target to $50.00 from $57.00.

Wuensch cited several headwinds facing the medical device company, including increased competition in the U.S. pulsed field ablation market, a stagnating left atrial appendage closure market, challenges in its urology segment, and a cybersecurity attack.

"We have lowered estimates eight times YTD, most recently on September 9, and while we want to believe that this is the final revision, our level of confidence in that is low," Wuensch said, adding that "resolving cybersecurity hangover

Boston Scientific (BSX) PT Lowered to $60 at Bernstein SocGen Group

Tue, 15 Sep 2026 09:40:55 -0400

Bernstein SocGen Group analyst Lee Hamnright lowered the price target on Boston Scientific (NYSE: BSX) to $60.00 (from $72.00) while maintaining a Outperform rating.

Belo Sun Mining Provides Update on Proceedings Related to the Installation License for the Volta Grande Gold Project In Brazil

Mon, 14 Sep 2026 07:00:00 -0400

TORONTO, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (TSX: BSX) (OTCQX: BSXGF) (the “Company” or “Belo Sun”) announced that its wholly-owned Brazilian subsidiary, Belo Sun Mineração Ltda. (“Belo Sun Mineração”), was formally notified on September 11, 2026, of a request for suspension of provisional relief (Suspensão de Tutela Provisória, or “STP”) filed by Brazil’s Federal Public Prosecutor’s Office (“MPF”) before the Brazilian Supreme Court (“STF”), concerning the Installation License (“LI”) for the Company’s Volta Grande Gold Project (the “Project”) in Pará, Brazil.

The STP proceeding (STP 1.156/PA) seeks to immediately suspend the